Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: pappy who wrote (522)	4/18/1998 1:28:00 AM
From: yosid	Read Replies (1) \| Respond to of 1754

Pappy ( That LCAV stock dividend must look real good now! ) If Summit can buy better technology via acquisition, I would think that would be enough to secure their installed base position. They would simply petition to replace their old machines with new, state of the art, lasers. What happens if the FED kills PPP? I can see BEAM and VISX being able to function using each other's patent rights without penalty, but how would a competing manufacturer be charged a royalty. I thought the technology was based on joint patents being used indivisible of each other. If this is true, I would think the fee charged by either Beam or Visx would be at their discretion. No matter what the patent participation, a new machine could not be produced without permission from both companies. Would this allow Summit to charge as much as Visx as a royalty?

To: pappy who wrote (522)	4/23/1998 2:24:00 AM
From: Jim Mac	Read Replies (1) \| Respond to of 1754

Hey, believe me, I wish I'D bought LCAV below $1. But I also wish I'd bought YHOO at $10 long ago...and Iomega before people went nuts for that one too. I can't help it if LCAV is overpriced now. That should be clear to anyone. The small float has been largely responsible for the run, which can't be sustained unless a mania develops. I like LCAV as a company, but LZRCF is even better, and LVCI is the best deal, partly because LVCI is the lowest-risk, LCAV is the highest-risk. LVCI can make $1.00-$1.50 fully-taxed in calendar 1999 (with hyperopia). Not true with LZRCF, and LCAV isn't likely to earn more than $0.25 fully-taxed in 1999.